Vikas Dandekar

Indians are ingesting too many antibiotics. As a result, antimicrobial resistance (AMR) is becoming a serious public health crisis, as many commonly used antibiotics are losing their effectiveness. Currently, about 70% of antibiotic treatments fail to work against infections, making it increasingly difficult to treat conditions that once had straightforward solutions. Each year, more patients experience recurring infections, both in outpatient and inpatient settings, and mortality rates continue to rise among those requiring critical care. Hosts Vikas Dandekar and Anirban Chowdhury talk to Dr Viny Kantroo of Indraprastha Apollo Hospitals, and Maneesh Paul of Orchid Pharma trying to understand if AMR could drastically alter healthcare as we know it, posing an unprecedented challenge to future generations.

23andMe, a pioneer in genetic testing, struggles to maintain its early success. As quickly as it soared, its market value plummeted, leaving the companys future uncertain. ET Prime examines the challenges faced by 23andMe, along with opportunities and potential implications for Indias genetic-testing market.

Unravelling precise family history and ancestry by simple at-home saliva tests zoomed 23andMe into the living rooms of millions of people in the US.

Doctors are grappling with a raft of unsparing hospital-acquired superbugs broadly known as anti-microbial resistance or AMR. Are bacterial infections the next big lethal adversary for mankind?

Narayana Health, led by Devi Shetty, is in advanced talks to acquire a controlling stake in Spire Healthcare Group amid a surge in the UK's private healthcare demand. The Indian medical group aims to secure a 51-75% stake, potentially taking the company private, leveraging positive shareholder sentiments and global financing.

Devi Shetty-led Narayana Hrudayalaya (rebranded Narayana Health) is in discussions with key shareholders of Spire Healthcare Group Plc to acquire a controlling stake in UK's largest private player in revenue in the segment, said people aware of the matter.

Private equity investors have been investing large sums of money in hospitals. Certain types of hospital chains are delivering healthy returns for such investors.

Private equity investors have been investing large sums of money in hospitals. Certain types of hospital chains are delivering healthy returns for such investors.

Private equity investors have been investing large sums of money in hospitals. Certain types of hospital chains are delivering healthy returns for such investors.

Millions of diabetes patients have to take a painful insulin injection to keep sugar levels in control. Cipla is introducing Afrezza, an inhaled insulin, in India. Will doctors and patients buy this option?